Articles tagged with Osteoporosis
A Loyola Medicine study found that 15.4% of osteoporosis patients taking bisphosphonates experienced bone fractures during a six-year follow-up period. Patients at high risk of fracture should be closely followed, especially as the drug holiday lengthens.
A UAB-led study published in The Lancet Diabetes & Endocrinology found that denosumab was superior to risedronate in increasing bone density in patients with glucocorticoid-induced osteoporosis. The 12-month study enrolled 795 patients and showed promising results for the new drug.
The International Osteoporosis Foundation's new interactive map reveals wide global variation in calcium intake, with low levels prevalent in Asia and Latin America. The map highlights the need for public health strategies to increase calcium intake throughout the lifespan.
Professor Cyrus Cooper has been named the winner of the annual Olof Johnell Science Award, recognizing his internationally recognized contributions to the field of osteoporosis. He leads an internationally competitive programme of research into musculoskeletal disorders, most notably osteoporosis.
Professor Nicholas Harvey received the prestigious IOF Medal of Achievement for his outstanding work in understanding early determinants of fracture risk and developing novel interventions. He has made significant contributions to the field of osteoporosis through his research and educational initiatives.
Researchers investigated barriers to advance care planning in prisons, finding profound patient mistrust and obstructive institutional policies. The study also explored the link between hypertension treatment and an increased risk of falls, suggesting that de-intensified blood pressure control may reduce recurrent falls.
A possible treatment for Hajdu-Cheney syndrome has been identified, which may also help with age-related osteoporosis. Researchers found that a medication called DAPT blocks osteoclast formation, reversing bone loss in mice with the disease.
Pooled data from 14 osteoporosis clinical trials indicate that reduced bone turnover markers are associated with lower vertebral fracture risks. The findings may aid in developing anti-resorptive drugs by optimizing dose and treatment schedules.
A new study found that community screening for osteoporosis reduced hip fractures by 28% in older women. Screening identified those at risk and led to targeted treatment, resulting in a significant decrease in hip fractures.
A large multicentre study found that community screening for osteoporosis using bone mineral density measurements and a questionnaire led to a 28% reduction in hip fractures among older women. The approach is estimated to prevent one hip fracture for every 111 women screened.
The FRAX calculator has been widely adopted globally, helping clinicians make informed decisions based on multiple scientifically validated risk factors. A recent study confirms that intervention thresholds based on fracture probabilities are highly effective in targeting high-risk individuals.
A systematic review by the International Osteoporosis Foundation reveals low dietary calcium intake in many Asian and Latin American countries, with the lowest average intake found among China, India, and Indonesia. The study emphasizes the need for increased calcium consumption to promote bone health in these regions.
The IOF Compendium documents the growing global burden of osteoporosis, with projected increases in fractures expected to pose a huge challenge on healthcare systems. The report outlines eight priority actions to stem this burden, including provision of Orthogeriatric and Fracture Liaison Services.
Daily calcium intake among adults varies widely around the world, with many areas at risk of bone health due to low intakes. Regional patterns show Southern and Eastern Asia having the lowest average intakes, while Northern Europe registers higher intakes.
Researchers used advanced mass spectrometry technology to create a molecular model that can aid in designing new osteoporosis treatments. The study's findings provide insights into the structure of a key receptor regulating calcium levels, paving the way for more effective and safer therapies.
The European Menopause and Andropause Society recommends a daily calcium intake of 700-1200mg for postmenopausal women to reduce the risk of osteoporosis. Calcium-rich foods should be prioritized over supplements, as excessive intake may cause harm.
Long-term treatment of osteoporosis is crucial for postmenopausal women to reduce fracture risk. New guidelines recommend reevaluating fracture risk after 3-5 years of bisphosphonate treatment and considering alternative therapies or continued treatment.
Researchers are developing a 'lab-on-a-chip' platform to study cellular communication in bone remodeling, aiming to improve our understanding of bone health and disease. The platform could also be used to test medications meant to halt bone loss, offering a potential solution for osteoporosis and related conditions.
A new treatment for osteoporosis has shown significant improvements in bone density and fracture protection. The study found that romosozumab reduced the risk of vertebral fractures by 48% and clinical fractures by 27%, offering better protection against fractures for high-risk patients.
A study found that less than half of detectable vertebral fractures are reported by radiologists, particularly in non-musculoskeletal radiologists. This under-reporting can lead to delayed diagnosis and treatment of osteoporosis, increasing the risk of future hip fractures.
A new Australian study reveals hip fractures are a major public health issue with high morbidity and mortality rates. The research found that individuals with hip fractures were 3.5 times more likely to die within 12 months compared to non-injured counterparts, with excess mortality risk higher in males than females.
A massive genetic study has identified 153 new gene variants linked to osteoporosis, which could lead to the development of a new treatment. The study found that removing a strongly implicated gene GPC6 in animal models resulted in increased bone thickness.
Researchers at the University of British Columbia have developed a new osteoporosis treatment using a compound derived from red sage, selectively blocking Cathepsin K enzyme activity in bone tissue. This approach may prevent negative side effects associated with current treatments.
Researchers discovered a causal link between senescent cells and age-related bone loss in mice. Targeting these cells increased bone mass and strength. The study's findings suggest that senolytic drugs may have widespread application in treating multiple chronic diseases, including osteoporosis.
Teriparatide therapy increases osteoblast activity and lifespan, but stopping treatment leads to increased fat cell formation in mice. This suggests therapies targeting parathyroid hormone receptors may prioritize osteoblast development over other cell fates.
A study by Cornell University researchers found that prolonged bisphosphonate use can alter the composition of bone, making it more brittle and susceptible to fractures. The study suggests that long-term treatment beyond FDA recommendations may increase the risk of atypical femoral fractures.
A UTA professor has received a grant to design a biomedical device that stimulates bone growth and could be used to treat osteoporosis. The device aims to strengthen bones of people with low bone mass conditions.
A study of over 2,500 women found that even brief bursts of high-intensity exercise, equivalent to a 1-2 minute run, can improve bone health. The research suggests that short periods of weight-bearing activity are more beneficial than longer continuous periods.
A nationwide Swedish study linked alendronate treatment to a lower risk of hip fractures in elderly patients using medium to high doses of anti-inflammatory medication. The research also found that longer treatment duration was associated with a greater reduction in fracture risk.
A comprehensive review highlights the most effective treatment options for co-managing type 2 diabetes and osteoporosis. Researchers suggest using medications like Metformin and DPP-4 inhibitors to protect bone health. Meanwhile, insulin therapy is recommended for achieving glycemic control in patients with T2D and fractures.
A new class of drug, romosozumab, has been shown to rapidly and significantly reduce the risk of vertebral fractures in postmenopausal women with osteoporosis. In a clinical trial, women treated with romosozumab had a 83% lower risk of vertebral fracture compared to those receiving placebo.
The ACR's updated clinical guideline provides recommendations for assessing fracture risk and treatment for adults and special patient populations. For all age groups, the panel strongly recommends optimizing calcium and vitamin D intake and implementing lifestyle modifications to prevent glucocorticoid-induced osteoporosis.
Research at the University of Missouri School of Medicine highlights the importance of understanding risk factors and following treatment plans to prevent osteoporosis-related fractures. The study emphasizes the need for preventive screening methods, cost-effective medications, and patient education to effectively manage the disease.
Increased yogurt intake was associated with higher hip bone density and reduced osteoporosis risk in older women and men. Vitamin D supplements also showed a significant association with reduced risks in both sexes.
The American College of Physicians strongly recommends the use of generic bisphosphonates or denosumab to reduce fracture risk in women with osteoporosis. The guideline advises physicians to prescribe generics over brand-name drugs and discuss medication adherence with patients.
The American College of Physicians recommends treating women with osteoporosis with bisphosphonates or denosumab, while men may also benefit from treatment to reduce vertebral fracture risk. The guideline emphasizes the importance of medication adherence and avoids estrogen therapy due to its associated risks.
A study published in the New England Journal of Medicine reveals a genetic mutation that makes bone vulnerable to bisphosphonates, increasing the risk of atypical femur fractures. The discovery highlights the need for personalized treatment approaches to prevent this complication.
A French study found that direct communication with fracture patients through a dedicated case manager increased post-fracture BMD testing rates by 20%. This approach empowered patients to demand testing and care, closing the care gap in osteoporosis treatment.
A new study confirms denosumab's short-term and long-term safety in treating postmenopausal osteoporosis. Women on long-term treatment experienced no increase in adverse effects compared to those on placebo or shorter treatment durations.
A new study found denosumab safe for treating postmenopausal osteoporosis over an extended period. The monoclonal antibody showed no increased risk of adverse events after 6 years of treatment, confirming its excellent safety and tolerability profile.
A recent study found that less than half of elderly hip fracture patients take vitamin D supplements, contradicting national recommendations. This suggests a need for improved advocacy and education about vitamin D supplementation.
A new study reveals that men are at a higher risk of mortality after osteoporosis-related fractures compared to women. The study found that men who require surgical treatment for an initial fracture are more likely to suffer a subsequent fracture within three years.
A systematic review of 37 randomized controlled trials found that exercise had a positive impact on muscle mass and function in healthy older adults, while dietary supplementation showed less consistent benefits. The combined effect of exercise and nutrition intervention varied depending on the individual's baseline health status.
A new study by Imperial College London suggests that bisphosphonates, a commonly used treatment for osteoporosis, may increase the risk of 'micro-cracks' in bone, leading to reduced mechanical strength. The research found that patients taking the drugs had more microcracks and weaker bones than those who were not on the medication.
A large study of postmenopausal women who suffered a hip fracture found low rates of osteoporosis assessment and treatment. Regular doctor visits were the strongest predictor of osteoporosis diagnosis and treatment.
A new review identifies four main themes addressing gaps in osteoporosis care, including public awareness, reimbursement, and epidemiology. The authors stress the need for increased implementation of systematic approaches to prevent secondary fractures and improved management of patients with medicines negatively affecting bone health.
The IOF-ECTS Position Paper proposes measuring specific bone turnover markers to detect low adherence to oral bisphosphonates, a common issue in chronic diseases. This early identification enables discussion and intervention with patients, potentially improving treatment efficacy.
A new study of 119 children with osteogenesis imperfecta found that bisphosphonate treatment did not change the radiological appearance of femur fractures.
The current approaches to preventing hip fractures have shown limited efficacy, with only a 50% reduction in risk. A new review suggests exploring complementary approaches and surgical interventions for patients at high risk, including prophylactic nailing and bone grafting.
The American Association of Clinical Endocrinologists and American College of Endocrinology have released new osteoporosis guidelines recommending that all postmenopausal women aged 50 and older be evaluated for osteoporosis risk. Successful treatment is defined as stable or increasing bone mineral density with no evidence of new fract...
New York University College of Dentistry has received a grant to investigate potential new compounds for treating osteoporosis. The researchers aim to understand the molecular mechanisms of parathyroid hormone-a related protein and its analogs to develop better-tolerated treatments.
A new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism reveals that menopausal hormone therapy (MHT) improves both bone mass and structure, with benefits persisting for at least two years after treatment ends.
The expert panel concludes that calcium and vitamin D supplements are generally appropriate for those with high risk of insufficiency and in individuals receiving osteoporosis treatment. The evidence favors use of calcium and vitamin D supplements for fracture reduction, particularly in those at greatest risk of insufficiency.
Early and aggressive treatment with biologic drugs may halt progressive bone loss in patients with RA. Biologic therapies targeting specific cytokines and signaling pathways show protective effects on the skeleton.
The International Osteoporosis Foundation presented five researchers with prestigious Young Investigator Research Awards for their notable osteoporosis research. The award winners were selected from 168 abstracts and received a prize of $1000, a certificate, and the opportunity to present their work at a high-profile session.
The implementation of Fracture Liaison Services (FLS) is crucial to identify and treat high-risk patients with osteoporosis, reducing the risk of secondary fractures. Studies have shown that FLS can significantly increase treatment rates and prevent secondary osteoporotic fractures.
A recent analysis of the ACTIVE trial results shows that abaloparatide-SC provides consistent protection against bone fractures in postmenopausal women with osteoporosis, regardless of baseline bone density or age. The therapy has been found to reduce fractures and increase bone mineral density in postmenopausal women with osteoporosis.
Abaloparatide stimulates bone formation without affecting resorption, reducing fractures in postmenopausal women with osteoporosis. The study's preclinical data are promising for continued development of abaloparatide as an osteoporosis treatment.
Researchers used genetic profiling to predict osteoporosis risk in individuals with high accuracy, improving classification by 12% compared to traditional clinical risk factors. The findings have the potential to revolutionize bone disease management and treatment for Australia's 1.2 million osteoporosis sufferers.
A new report by the International Osteoporosis Foundation identifies 10 major care gaps that are preventing early assessment and treatment of osteoporosis. The report highlights the need for better case finding, communication, and public awareness to tackle the global healthcare crisis arising from fragility fractures.